Osteoporosis drugs linked to lower dementia risk in new study

Study finds bone drug benefits

Researchers in HKUMed's LKS Faculty of Medicine's Department of Pharmacology and Pharmacy examined information from over 120,000 seniors. Their findings indicate that patients taking nitrogen-containing bisphosphonates were significantly less likely to develop Alzheimer's disease or other dementias. The specific risk reduction reached up to 24 percent for those using these established bone treatments. This research was published in the journal Alzheimer's & Dementia on November 9, 2026.

Existing drugs offer brain protection

Nitrogen-containing bisphosphonates such as alendronate and zoledronate are widely prescribed to prevent bone loss and fractures in aging populations. While these drugs may affect biological mechanisms linked to Alzheimer's disease, they function by decelerating the degradation of bone material. Currently over 55 million people globally suffer from dementia, and this figure is expected to reach 139 million by the year 2050. The World Health Organization has identified this condition as a major global health priority requiring affordable prevention strategies.

Costs drive interest in new uses

New medications designed to slow Alzheimer's progression face high costs and limited suitability for some patients despite recent approvals. These obstacles have increased interest in identifying existing medications that might offer benefits beyond their original intended treatments. Osteoporosis and dementia often affect the same older adults who share risk factors like older age and low physical activity. Earlier studies showed that osteoporosis and fractures act as separate risk factors leading to dementia in later life.